Taysha Gene Therapies (TSHA) Revenue (2023 - 2025)

Taysha Gene Therapies (TSHA) has 3 years of Revenue data on file, last reported at $1.2 million in Q4 2025.

• For the quarter ending Q4 2025, Revenue fell 40.06% year-over-year to $1.2 million; the trailing twelve-month figure through Mar 2026 stood at $3.2 million (down 55.73% YoY), and the FY2025 full-year result was $5.5 million, down 34.0% from the prior year.
• Revenue declined to $1.2 million in Q4 2025, from $2.0 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $4.7 million in Q3 2023 to a low of $1.1 million in Q2 2024.
• A 3-year average of $2.7 million and a median of $2.3 million in 2025 frame the typical range for Revenue.
• Across the five-year window, Revenue plunged 62.33% in 2024 and soared 78.6% in 2025, its largest moves.
• Tracing TSHA's Revenue over 3 years: stood at $3.6 million in 2023, then plunged by 43.9% to $2.0 million in 2024, then slumped by 40.06% to $1.2 million in 2025.
• Business Quant data shows TSHA's Revenue at $1.2 million in Q4 2025, $2.0 million in Q2 2025, and $2.3 million in Q1 2025.